ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
REGENXBIO Inc

REGENXBIO Inc (RGNX)

7.82
-0.25
(-3.10%)
Closed February 04 3:00PM
8.21
0.39
(4.99%)
After Hours: 6:58PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
8.21
Bid
7.78
Ask
9.04
Volume
959,910
7.51 Day's Range 8.03
6.56 52 Week Range 28.80
Market Cap
Previous Close
8.07
Open
7.825
Last Trade Time
Financial Volume
US$ 7,453,137
VWAP
7.7644
Average Volume (3m)
1,373,602
Shares Outstanding
49,545,071
Dividend Yield
-
PE Ratio
-1.47
Earnings Per Share (EPS)
-5.32
Revenue
90.24M
Net Profit
-263.49M

About REGENXBIO Inc

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
REGENXBIO Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RGNX. The last closing price for REGENXBIO was US$8.07. Over the last year, REGENXBIO shares have traded in a share price range of US$ 6.56 to US$ 28.80.

REGENXBIO currently has 49,545,071 shares outstanding. The market capitalization of REGENXBIO is US$399.83 million. REGENXBIO has a price to earnings ratio (PE ratio) of -1.47.

RGNX Latest News

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 PR Newswire ROCKVILLE, Md., Jan. 30, 2025 ROCKVILLE, Md., Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:...

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases PR Newswire ROCKVILLE, Md., Jan. 14, 2025 REGENXBIO to receive $110...

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PR Newswire NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 Pivotal data evaluating the safety and efficacy of the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.364.585987261157.858.637.237726887.84102074CS
40.080.9840098400988.138.846.5611142807.56982233CS
12-3.14-27.665198237911.3512.226.5613736028.42714296CS
26-4-32.7600327612.2113.486.568823729.23680818CS
52-3.85-31.923714759512.0628.86.5676212112.48051419CS
156-17.04-67.485148514925.2535.736.5652797817.36579385CS
260-35.83-81.357856494144.0454.976.5647936023.97752501CS

RGNX - Frequently Asked Questions (FAQ)

What is the current REGENXBIO share price?
The current share price of REGENXBIO is US$ 8.21
How many REGENXBIO shares are in issue?
REGENXBIO has 49,545,071 shares in issue
What is the market cap of REGENXBIO?
The market capitalisation of REGENXBIO is USD 399.83M
What is the 1 year trading range for REGENXBIO share price?
REGENXBIO has traded in the range of US$ 6.56 to US$ 28.80 during the past year
What is the PE ratio of REGENXBIO?
The price to earnings ratio of REGENXBIO is -1.47
What is the cash to sales ratio of REGENXBIO?
The cash to sales ratio of REGENXBIO is 4.3
What is the reporting currency for REGENXBIO?
REGENXBIO reports financial results in USD
What is the latest annual turnover for REGENXBIO?
The latest annual turnover of REGENXBIO is USD 90.24M
What is the latest annual profit for REGENXBIO?
The latest annual profit of REGENXBIO is USD -263.49M
What is the registered address of REGENXBIO?
The registered address for REGENXBIO is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the REGENXBIO website address?
The website address for REGENXBIO is www.regenxbio.com
Which industry sector does REGENXBIO operate in?
REGENXBIO operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
IVVDInvivyd Inc
US$ 1.055
(194.94%)
448.53M
HCWBHCW Biologics Inc
US$ 0.6265
(125.20%)
344.42M
UOKAMDJM Ltd
US$ 0.2293
(76.38%)
354.09M
GHRSGH Research PLC
US$ 17.9991
(69.80%)
10.31M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 234.64
(61.82%)
392
CYNCYNGN Inc
US$ 0.1169
(-56.70%)
75.52M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.1943
(-54.61%)
327.95M
VIRXViracta Therapeutics Inc
US$ 0.0741
(-51.09%)
9.37M
BOWNUBowen Acquisition Corporation
US$ 3.39
(-49.55%)
17.28k
PITAHeramba Electric PLC
US$ 0.503
(-44.11%)
1.37M
IVVDInvivyd Inc
US$ 1.055
(194.94%)
448.53M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0462
(27.98%)
434.24M
NVDANVIDIA Corporation
US$ 116.66
(-2.84%)
371.47M
UOKAMDJM Ltd
US$ 0.2293
(76.38%)
354.09M
HCWBHCW Biologics Inc
US$ 0.6265
(125.20%)
344.42M

RGNX Discussion

View Posts
Monksdream Monksdream 1 month ago
RGNX, under $8
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
RGNX under $10
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
36M share trading float.

RGNX
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones
6:31 am ET September 13, 2021 (Benzinga) Print
AbbVie (NYSE:ABBV) and REGENXBIO Inc. (NASDAQ:RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.

Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials. AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO shall participate in U.S. commercialization efforts as provided under a mutually agreed upon commercialization plan.

"We are committed to finding solutions for patients living with difficult-to-treat retinal diseases and to helping preserve and protect our patients from visual impairment and devastating vision loss," said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. "In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases."

"AbbVie is a strong, complementary partner for REGENXBIO. We expect to leverage AbbVie's global developmental and commercial infrastructure within eye care with our expertise in AAV gene therapy clinical development and deep in-house knowledge of manufacturing and production to continue the development of RGX-314," said Kenneth T. Mills, president and chief executive officer of REGENXBIO.

Under the terms of the agreement, AbbVie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development, regulatory and commercial milestones. REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the U.S. AbbVie will pay REGENXBIO tiered royalties on net sales of RGX-314 outside the U.S. In addition, REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead manufacturing of RGX-314 for commercial supply outside the U.S.
πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
https://www.google.com/amp/s/www.nasdaq.com/article/4-gene-therapy-players-likely-to-become-buyout-targets-in-2019-cm1125990/amp
πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
I believe the buyout is in a distance future. JUNO has the same trading behavior before buyout was announced!
πŸ‘οΈ0
Zmill Zmill 6 years ago
is there an argument for a BO? https://msmoneymoves.com/2019/05/28/could-this-biotech-stock-get-bought-for-5-5-billion-either-way-im-buying-it/
πŸ‘οΈ0
BlackEyePatch BlackEyePatch 6 years ago
Strong buy @ 50!!!!
πŸ‘οΈ0
stocktrademan stocktrademan 6 years ago
RGNX buy 66.90























normal chart




log chart



πŸ‘οΈ0
StockLearner2011 StockLearner2011 7 years ago
Hope no more form 4s for insider selling
πŸ‘οΈ0
StockLearner2011 StockLearner2011 7 years ago
Let’s see how tomorrow will be
πŸ‘οΈ0
StockLearner2011 StockLearner2011 7 years ago
Why insiders sold at $34 and $37 while the target price is $90? Anybody has any clue?
πŸ‘οΈ0
StockLearner2011 StockLearner2011 7 years ago
$45 soon! Yummy
πŸ‘οΈ0
stocktrademan stocktrademan 8 years ago
RGNX bullish 14.39



normal chart


log chart

πŸ‘οΈ0
protagonist12 protagonist12 9 years ago
Agreed, would like to to see the stock come down to single digits before buying though. Still only in preclinical trials and burning a ton of cash.
πŸ‘οΈ0
floWteiuQ floWteiuQ 9 years ago
Interesting play here for the long term. Very good technology with a lot of prospects for them and licensing.
πŸ‘οΈ0
protagonist12 protagonist12 9 years ago
RGNX no bid support, too early still, listed VC...
πŸ‘οΈ0